Product Description
Mechanisms of Action: CAR-T,ERBB2
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aurora BioPharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ACTRN12624001334594 | P1 |
Not yet recruiting |
Healthy Volunteers |
2025-06-01 |
|
ACTRN12624000562572 | P1 |
Not yet recruiting |
Healthy Volunteers |
2025-01-03 |